## UTHR: United Therapeutics Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.44 indicates fundamental undervaluation. Quality metrics strong (ROE 20%, ROA 13%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($483.40)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 1
- **Sentiment:** Bearish (Bullish: 0, Bearish: 0)

**1. United Therapeutics (NASDAQ:UTHR) Director Sells $495,950.00 in Stock**
- Source: MarketBeat | 20251216T230922 | Somewhat-Bearish | Relevance: 100%
- United Therapeutics Director Christopher Patusky sold 1,000 shares of the company's stock for $495,950, reducing his stake by over 40%. The company recently reported Q3 EPS of $7.16, beating estimates, but revenue of $799.5 million missed expectations. Analysts currently hold a "Moderate Buy" consensus rating with a $505 target price for United Therapeutics.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 25 ($16.15M) |
| Sells | 67 ($38.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Blackrock Inc.: 12.4% (+0.4%)
- Vanguard Group Inc: 10.3% (-0.7%)
- Renaissance Technolo: 5.1% (+2.6%)
- Avoro Capital Adviso: 4.7% (-14.7%)
- State Street Corpora: 4.5% (-11.3%)

### Key Risks

1. Heavy insider selling: $39M sold (67 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +2.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.44 suggests fair value with growth premium. Forward P/E 17.8x stretched relative to 5% growth. Quality metrics strong (ROA 13%, margin 41%). Balance sheet: strong liquidity (6.4x), low leverage (D/E 0.12). Insider selling cluster ($38.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.9B |
| Beta | 0.86 |
| 52W Range | $266.98 - $513.93 |
| Short Interest | 5.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.44 |
| Forward P/E | 17.8 |
| Current P/E | 18.7 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 2.4% to 4.9% (+2.5% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 81st percentile. MRS_5 at 0.9% confirms short-term momentum alignment. AM_20 at 4.1% shows strong absolute momentum above own 20MA. Outperforming sector by 4.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.14), confirming momentum. Elevated volume (1.3x 20MA), institutional activity likely. OFD pattern: -DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.87% (CS: 82) | Strong |
| RSI_14 | 69.1 | Neutral |
| MACD Histogram | 1.14 | Bullish |
| vs SMA20 | 1.041x | Above |
| vs SMA50 | 1.099x | Above |
| vs SMA200 | 1.420x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $507.00
- **Stop Loss:** $483.40 (4.7% risk)
- **Target:** $554.20 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 40
- **Position Value:** $20,280.00
- **Portfolio %:** 20.28%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-25 (Est: $6.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.96 | $7.16 | +2.9% |
| 2025Q2 | $6.94 | $6.41 | -7.6% |
| 2025Q1 | $6.28 | $6.63 | +5.6% |
| 2024Q4 | $6.27 | $6.19 | -1.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*